Neoleukin Therapeutics (NLTX) Financials

Neoleukin Therapeutics logo
$23.93 +0.03 (+0.13%)
As of 11/13/2026
Annual Income Statements for Neoleukin Therapeutics

Annual Income Statements for Neoleukin Therapeutics

This table shows Neoleukin Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
-22 -37 -50 -32 -69 -33 -61 -55 -36 -75 -90
Consolidated Net Income / (Loss)
-22 -37 -50 -32 -69 -33 -61 -55 -36 -75 -90
Net Income / (Loss) Continuing Operations
-22 -37 -50 -32 -69 -33 -61 -55 -36 -75 -90
Total Pre-Tax Income
-22 -37 -50 -32 -69 -33 -61 -55 -53 -75 -90
Total Operating Income
-21 -38 -51 -33 -71 -34 -61 -57 -56 -83 -103
Total Gross Profit
0.00 0.00 0.00 25 0.00 0.00 0.00 0.00 0.00 0.93 0.00
Total Revenue
0.00 0.00 0.00 25 0.00 0.00 0.00 0.00 0.00 0.93 0.00
Operating Revenue
- 0.00 - 25 - - - - 0.00 0.93 0.00
Total Cost of Revenue
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses
21 38 51 58 71 34 61 57 56 84 103
Selling, General & Admin Expense
5.54 9.26 15 16 19 17 22 9.01 11 23 28
Research & Development Expense
16 28 36 42 52 24 39 48 44 61 75
Total Other Income / (Expense), net
-0.52 0.64 0.94 1.04 1.52 0.45 0.01 1.33 2.91 7.46 13
Interest Expense
0.00 0.00 0.00 0.00 - - -0.02 0.00 0.01 0.01 0.01
Interest & Investment Income
- - - - - - - 1.34 2.95 8.47 12
Other Income / (Expense), net
-0.52 0.64 0.94 1.04 1.52 0.45 -0.01 -0.01 -0.03 -0.99 1.44
Basic Earnings per Share
($1.73) ($1.96) ($2.14) ($1.34) ($2.57) ($0.64) ($1.10) ($139.88) $0.00 ($4.28) ($4.24)
Weighted Average Basic Shares Outstanding
12.64M 18.89M 23.45M 23.52M 27.03M 51.83M 55.04M 394.53K 0.00 17.57M 21.33M
Diluted Earnings per Share
($1.73) ($1.96) ($2.14) ($1.34) ($2.57) ($0.64) ($1.10) ($139.88) $0.00 ($4.28) ($4.24)
Weighted Average Diluted Shares Outstanding
12.64M 18.89M 23.45M 23.52M 27.03M 51.83M 55.04M 394.53K 0.00 17.57M 21.33M
Weighted Average Basic & Diluted Shares Outstanding
12.64M 18.89M 23.45M 23.52M 27.03M 51.83M 42.49M 42.82M 12.85M 14.93M 15.57M

Quarterly Income Statements for Neoleukin Therapeutics

This table shows Neoleukin Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Income / (Loss) Attributable to Common Shareholders
-17 -18 -20 -20 -23 -22 -21 -25 -31 -34 -29
Consolidated Net Income / (Loss)
-17 -18 -20 -20 -23 -22 -21 -25 -31 -34 -29
Net Income / (Loss) Continuing Operations
-17 -18 -20 -20 -23 -22 -21 -25 -31 -34 -29
Total Pre-Tax Income
-17 -19 -20 -20 -23 -23 -21 -23 -31 -35 -29
Total Operating Income
-19 -20 -22 -22 -26 -26 -24 -28 -33 -37 -32
Total Gross Profit
0.00 0.93 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Revenue
0.00 0.93 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Cost of Revenue
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Operating Expenses
19 21 22 22 26 26 24 28 33 37 32
Selling, General & Admin Expense
5.24 5.32 5.90 6.17 8.16 6.72 6.56 6.89 8.20 11 8.85
Research & Development Expense
14 16 16 15 18 19 17 21 25 25 24
Total Other Income / (Expense), net
1.72 1.50 1.82 1.85 3.27 2.85 2.70 4.30 2.42 2.04 3.21
Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Interest & Investment Income
2.32 2.04 1.84 2.27 3.21 2.93 2.74 2.67 2.26 2.05 3.24
Other Income / (Expense), net
-0.60 -0.53 -0.02 -0.41 0.07 -0.07 -0.04 1.63 0.15 -0.01 -0.03
Other Gains / (Losses), net
0.14 0.14 0.14 0.14 - 1.21 0.15 - - 0.14 0.14
Basic Earnings per Share
($1.00) ($1.09) ($1.19) ($1.00) ($1.08) ($1.05) ($0.99) ($1.12) ($1.39) ($1.53) ($1.05)
Weighted Average Basic Shares Outstanding
16.90M 16.94M 16.95M 17.57M 21.00M 21.06M 21.17M 21.33M 22.31M 22.55M 27.70M
Diluted Earnings per Share
($1.00) ($1.09) ($1.19) ($1.00) ($1.08) ($1.05) ($0.99) ($1.12) ($1.39) ($1.53) ($1.05)
Weighted Average Diluted Shares Outstanding
16.90M 16.94M 16.95M 17.57M 21.00M 21.06M 21.17M 21.33M 22.31M 22.55M 27.70M
Weighted Average Basic & Diluted Shares Outstanding
12.98M 12.99M 14.85M 14.93M 14.26M 14.27M 15.49M 15.57M 15.80M 20.01M 20.70M

Annual Cash Flow Statements for Neoleukin Therapeutics

This table details how cash moves in and out of Neoleukin Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
25 -7.23 20 25 66 50 -50 11 67 -12 -33
Net Cash From Operating Activities
-20 -30 -45 -32 -15 -25 -48 -53 -51 -71 -77
Net Cash From Continuing Operating Activities
-20 -30 -45 -32 -15 -25 -48 -53 -51 -71 -77
Net Income / (Loss) Continuing Operations
-22 -37 -50 -32 -69 -33 -61 -55 -36 -75 -90
Consolidated Net Income / (Loss)
-22 -37 -50 -32 -69 -33 -61 -55 -36 -75 -90
Depreciation Expense
- - 0.36 0.29 0.34 0.79 1.31 3.20 3.26 3.20 3.04
Amortization Expense
- - - - 0.19 1.04 0.97 0.00 -0.07 -2.37 -4.49
Non-Cash Adjustments To Reconcile Net Income
2.04 1.97 3.28 6.19 55 6.51 11 1.25 -15 6.58 12
Changes in Operating Assets and Liabilities, net
-0.45 4.82 1.82 -6.47 -1.95 0.37 -0.01 -2.09 -3.35 -2.87 2.44
Net Cash From Investing Activities
-48 -48 64 56 -0.69 -2.22 -3.26 -2.23 26 -125 14
Net Cash From Continuing Investing Activities
-48 -48 64 56 -0.69 -2.22 -3.26 -2.23 26 -125 14
Purchase of Property, Plant & Equipment
-0.03 -0.71 -0.49 - -0.88 -2.22 -3.26 -2.23 -0.32 -0.81 -1.18
Purchase of Investments
-61 -106 -6.00 - - - 0.00 - 0.00 -198 -270
Sale and/or Maturity of Investments
13 59 71 56 - - 0.00 0.00 5.00 74 285
Net Cash From Financing Activities
93 71 0.42 0.57 82 77 0.73 67 92 184 30
Net Cash From Continuing Financing Activities
93 71 0.42 0.57 82 77 0.73 67 92 184 30
Repayment of Debt
0.00 -0.00 -0.02 -0.03 - - - -0.00 -0.03 -4.29 0.00
Repurchase of Common Equity
-6.21 -4.69 - - -0.35 -0.36 - - - 0.00 -0.24
Payment of Dividends
- - - - - - - - 0.00 -2.86 0.00
Issuance of Common Equity
98 75 - - 81 72 0.37 0.00 92 190 30
Other Financing Activities, net
1.12 0.44 0.44 0.60 1.55 5.62 0.36 0.07 0.17 1.62 0.21
Cash Interest Paid
0.00 0.00 0.00 0.00 - - - 0.00 0.01 0.01 0.01

Quarterly Cash Flow Statements for Neoleukin Therapeutics

This table details how cash moves in and out of Neoleukin Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents
1.76 -39 -44 70 -66 -12 12 33 20 -12 -34
Net Cash From Operating Activities
-22 -16 -16 -17 -21 -19 -20 -17 -26 -24 -29
Net Cash From Continuing Operating Activities
-22 -16 -16 -17 -21 -19 -20 -17 -26 -24 -29
Net Income / (Loss) Continuing Operations
-17 -18 -20 -20 -23 -22 -21 -25 -31 -34 -29
Consolidated Net Income / (Loss)
-17 -18 -20 -20 -23 -22 -21 -25 -31 -34 -29
Depreciation Expense
0.81 0.80 0.80 0.79 0.75 0.75 0.76 0.78 0.85 0.81 0.82
Amortization Expense
-0.44 -0.31 -0.68 -0.95 -1.73 -1.46 -0.80 -0.49 -0.37 -0.34 -2.19
Non-Cash Adjustments To Reconcile Net Income
1.31 1.26 2.01 2.52 3.54 2.18 2.83 2.94 3.06 7.28 4.55
Changes in Operating Assets and Liabilities, net
-6.42 0.85 2.53 -0.35 -0.68 1.08 -1.34 4.09 1.27 2.97 -3.30
Net Cash From Investing Activities
30 -24 -29 -103 -45 7.45 22 30 46 6.10 -166
Net Cash From Continuing Investing Activities
30 -24 -29 -103 -45 7.45 22 30 46 6.10 -166
Purchase of Property, Plant & Equipment
-0.07 -0.46 -0.17 -0.12 -0.78 -0.15 -0.13 -0.13 -0.28 -0.35 -0.32
Purchase of Investments
0.00 -43 -38 -118 -89 -60 -77 -43 -83 -113 -241
Sale and/or Maturity of Investments
30 20 8.75 16 45 68 100 73 130 119 75
Net Cash From Financing Activities
-6.52 0.40 0.13 190 0.00 0.05 9.71 21 0.20 5.98 162
Net Cash From Continuing Financing Activities
-6.52 0.40 0.13 190 0.00 0.05 9.71 21 0.20 5.98 162
Repurchase of Common Equity
- - - - - - - -0.08 - - 0.02
Issuance of Common Equity
- - - - - - - 21 - - -5.91
Other Financing Activities, net
0.62 0.40 0.13 0.53 0.02 0.08 0.05 0.07 0.20 0.02 33

Annual Balance Sheets for Neoleukin Therapeutics

This table presents Neoleukin Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets
113 154 110 78 147 211 163 109 223 336 289
Total Current Assets
75 103 109 77 144 195 144 85 200 316 272
Cash & Equivalents
40 32 52 77 143 193 142 82 148 137 104
Short-Term Investments
35 71 56 - - - 0.00 0.00 49 176 165
Prepaid Expenses
- - - - - - - 2.70 3.19 3.52 2.76
Plant, Property, & Equipment, net
0.09 0.85 0.91 0.40 2.06 0.00 0.00 20 17 15 13
Total Noncurrent Assets
38 50 0.60 0.05 1.37 16 19 4.43 5.05 4.39 4.04
Noncurrent Note & Lease Receivables
- - - - - - - 0.09 0.10 0.07 0.02
Other Noncurrent Operating Assets
- 0.00 0.60 0.05 0.80 16 19 4.34 4.95 4.31 4.02
Total Liabilities & Shareholders' Equity
113 154 110 78 147 211 163 109 223 336 289
Total Liabilities
4.92 9.72 11 4.95 5.34 19 20 11 37 25 24
Total Current Liabilities
4.79 9.52 11 4.63 4.74 7.89 8.64 6.65 23 15 16
Accounts Payable
4.79 9.52 11 4.62 4.13 7.18 7.42 0.63 2.60 1.34 1.95
Accrued Expenses
- - - - - - - 5.32 17 9.73 11
Other Current Liabilities
- - - 0.01 0.62 0.71 1.22 0.70 2.88 4.09 3.70
Total Noncurrent Liabilities
0.13 0.20 0.49 0.32 0.59 11 12 3.99 14 10 7.31
Capital Lease Obligations
- - - 0.01 - 0.11 - 0.07 0.07 0.03 0.01
Other Noncurrent Operating Liabilities
0.13 0.20 0.49 - 0.59 11 12 3.92 14 10 7.30
Commitments & Contingencies
0.00 0.00 0.00 0.00 - - - 0.00 - - 0.00
Total Equity & Noncontrolling Interests
108 145 99 73 142 191 143 -146 186 310 265
Total Preferred & Common Equity
108 145 99 73 142 191 143 -146 186 310 265
Preferred Stock
0.00 0.00 0.00 - 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
108 145 99 73 142 191 143 -146 186 310 265
Common Stock
220 293 297 303 441 524 536 5.10 373 573 618
Retained Earnings
-111 -148 -199 -230 -300 -333 -393 -151 -187 -262 -353

Quarterly Balance Sheets for Neoleukin Therapeutics

This table presents Neoleukin Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets
90 195 180 164 315 297 288 263 244 378
Total Current Assets
80 174 159 144 296 279 271 247 229 363
Cash & Equivalents
25 150 111 67 71 59 71 124 112 79
Short-Term Investments
53 19 43 72 222 216 194 119 113 281
Prepaid Expenses
- 4.61 5.24 4.65 3.80 4.47 5.11 3.57 3.52 3.02
Plant, Property, & Equipment, net
0.48 16 16 16 15 14 13 13 12 11
Total Noncurrent Assets
9.21 4.73 4.61 4.41 4.10 4.08 3.83 3.89 3.72 3.98
Noncurrent Note & Lease Receivables
- 0.09 0.10 0.08 0.06 0.05 0.03 0.02 0.01 0.01
Other Noncurrent Operating Assets
9.21 4.65 4.51 4.32 4.04 4.04 3.80 3.88 3.71 3.97
Total Liabilities & Shareholders' Equity
90 195 180 164 315 297 288 263 244 378
Total Liabilities
14 25 25 27 24 24 22 25 27 23
Total Current Liabilities
5.21 12 13 16 14 15 15 19 22 18
Accounts Payable
3.66 1.52 1.72 1.68 3.06 2.06 1.54 4.69 3.29 2.29
Accrued Expenses
- 6.82 7.14 10 6.85 9.10 9.42 11 15 13
Other Current Liabilities
1.55 3.47 4.21 3.68 4.18 4.28 3.74 3.05 3.03 3.01
Total Noncurrent Liabilities
9.14 13 12 11 9.41 8.62 7.58 6.49 5.73 4.94
Capital Lease Obligations
0.01 - 0.05 0.04 0.02 0.01 0.01 0.00 0.00 0.00
Other Noncurrent Operating Liabilities
9.13 13 12 11 9.40 8.61 7.58 6.49 5.72 4.94
Commitments & Contingencies
- - - - - - - 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
75 171 155 137 292 273 266 238 217 355
Total Preferred & Common Equity
75 171 155 137 292 273 266 238 217 355
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
75 171 155 137 292 273 266 238 217 355
Common Stock
547 375 378 380 577 580 593 621 635 802
Retained Earnings
-472 -204 -223 -243 -285 -307 -328 -384 -418 -447

Annual Metrics And Ratios for Neoleukin Therapeutics

This table displays calculated financial ratios and metrics derived from Neoleukin Therapeutics' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding
17,211,986.00 23,423,150.00 23,464,930.00 23,537,368.00 38,332,943.00 41,894,382.00 42,428,134.00 42,594,602.00 9,397,901.00 - 15,489,800.00
DEI Adjusted Shares Outstanding
17,211,986.00 23,423,150.00 23,464,930.00 23,537,368.00 38,332,943.00 41,894,382.00 42,428,134.00 42,594,602.00 9,397,901.00 - 15,489,800.00
DEI Earnings Per Adjusted Shares Outstanding
-1.27 -1.58 -2.14 -1.34 -1.81 -0.79 -1.43 -1.30 -3.86 - -5.83
Growth Metrics
- - - - - - - - - - -
Revenue Growth
0.00% 0.00% 0.00% 0.00% -100.00% 0.00% 0.00% 0.00% 0.00% 0.00% -100.00%
EBITDA Growth
-2.28% -69.26% -34.64% 37.19% -120.23% 54.35% -85.76% 8.74% 1.70% -59.00% -24.85%
EBIT Growth
7.28% -69.26% -35.62% 37.06% -119.89% 52.08% -82.44% 6.90% 1.62% -51.36% -21.88%
NOPAT Growth
4.63% -76.41% -35.79% 36.18% -117.51% 52.47% -79.96% 6.89% 1.65% -48.62% -25.09%
Net Income Growth
9.02% -69.27% -35.62% 37.06% -119.86% 52.08% -82.38% 9.07% 34.20% -106.91% -20.24%
EPS Growth
37.09% -13.29% -9.18% 37.38% -91.79% 75.10% -71.88% -12,616.36% 100.00% 0.00% 0.93%
Operating Cash Flow Growth
-15.91% -49.13% -47.95% 29.39% 51.25% -59.64% -93.52% -11.07% 2.65% -37.30% -9.31%
Free Cash Flow Firm Growth
-9.13% -45.93% -56.15% 20.67% -89.01% 54.71% -85.50% -26.56% 80.00% -498.92% -4.97%
Invested Capital Growth
8.74% -86.75% -8.97% 53.79% 66.92% 12.38% 132.22% 4,099.50% -166.39% 81.89% -105.64%
Revenue Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth
10.02% -17.76% -10.32% 27.16% -4.06% -16.06% -4.22% 7.36% -7.63% -10.71% -3.53%
EBIT Q/Q Growth
10.02% -17.76% -11.12% 26.49% -4.86% -15.79% -4.37% 5.88% -5.91% -9.32% -4.06%
NOPAT Q/Q Growth
9.45% -18.48% -11.01% 25.61% -4.50% -14.54% -4.36% 5.83% -5.83% -8.94% -6.18%
Net Income Q/Q Growth
10.00% -17.76% -11.13% 26.49% -4.85% -15.79% -4.34% 6.90% 27.04% -41.12% -6.13%
EPS Q/Q Growth
5.98% -12.64% -10.88% 26.78% -0.78% 0.00% -5.77% -2,509.70% 100.00% -105.07% -2.91%
Operating Cash Flow Q/Q Growth
11.89% -20.01% -6.19% 5.48% 25.03% -22.99% -6.59% -12.77% 2.24% -0.75% 0.09%
Free Cash Flow Firm Q/Q Growth
11.03% -21.99% -3.41% -5.67% 9.85% -24.61% -6.40% -36.69% 67.83% -22.05% -0.60%
Invested Capital Q/Q Growth
-33.57% -16.60% -64.16% 57.54% -296.64% -52.10% 784.48% 1,464.32% -238.78% -30.13% -3,108.03%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
0.00% 0.00% 0.00% 100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 100.00% 0.00%
EBITDA Margin
0.00% 0.00% 0.00% -125.17% 0.00% 0.00% 0.00% 0.00% 0.00% -9,010.27% 0.00%
Operating Margin
0.00% 0.00% 0.00% -130.50% 0.00% 0.00% 0.00% 0.00% 0.00% -8,930.27% 0.00%
EBIT Margin
0.00% 0.00% 0.00% -126.32% 0.00% 0.00% 0.00% 0.00% 0.00% -9,099.78% 0.00%
Profit (Net Income) Margin
0.00% 0.00% 0.00% -126.34% 0.00% 0.00% 0.00% 0.00% 0.00% -8,123.68% 0.00%
Tax Burden Percent
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 68.95% 99.24% 100.00%
Interest Burden Percent
100.00% 100.00% 100.01% 100.01% 100.00% 100.00% 99.97% 97.64% 94.72% 89.96% 88.67%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
-30.24% -29.24% -41.21% -36.82% -64.79% -19.99% -36.33% -45.71% -25.52% -30.28% -31.41%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -11,112.75% -654.25% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
0.00% 0.00% 0.00% -33.61% 0.00% 0.00% 0.00% 0.00% 0.00% -30.15% 0.00%
Return on Assets (ROA)
0.00% 0.00% 0.00% -33.61% 0.00% 0.00% 0.00% 0.00% 0.00% -26.92% 0.00%
Return on Common Equity (ROCE)
-30.24% -29.24% -41.21% -36.82% -64.79% -19.99% -36.33% 0.54% -3.61% -30.28% -31.41%
Return on Equity Simple (ROE_SIMPLE)
-20.16% -25.58% -50.75% -43.46% -49.01% -17.40% -42.48% 37.87% -19.52% -24.21% 0.00%
Net Operating Profit after Tax (NOPAT)
-15 -26 -36 -23 -50 -24 -42 -40 -39 -58 -72
NOPAT Margin
0.00% 0.00% 0.00% -91.35% 0.00% 0.00% 0.00% 0.00% 0.00% -6,251.19% 0.00%
Net Nonoperating Expense Percent (NNEP)
-8.99% -8.01% -11.03% -9.46% -17.97% -5.76% -10.87% -13.93% 1.86% -6.80% -6.20%
Return On Investment Capital (ROIC_SIMPLE)
- - - - - - - - -20.91% -18.63% -27.31%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
0.00% 0.00% 0.00% 63.34% 0.00% 0.00% 0.00% 0.00% 0.00% 2,444.65% 0.00%
R&D to Revenue
0.00% 0.00% 0.00% 167.16% 0.00% 0.00% 0.00% 0.00% 0.00% 6,585.62% 0.00%
Operating Expenses to Revenue
0.00% 0.00% 0.00% 230.50% 0.00% 0.00% 0.00% 0.00% 0.00% 9,030.27% 0.00%
Earnings before Interest and Taxes (EBIT)
-22 -37 -50 -32 -69 -33 -61 -57 -56 -84 -102
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-22 -37 -50 -31 -69 -31 -58 -53 -52 -83 -103
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.29 1.66
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.29 1.66
Price to Revenue (P/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 434.14 0.00
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 96.44 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage
-1.07 -1.05 -1.07 -1.08 -1.03 -1.01 -1.00 -0.93 -0.98 -1.03 -1.01
Leverage Ratio
1.07 1.06 1.09 1.10 1.05 1.07 1.12 1.13 1.17 1.12 1.09
Compound Leverage Factor
1.07 1.06 1.09 1.10 1.05 1.07 1.12 1.10 1.10 1.01 0.96
Debt to Total Capital
0.00% 0.00% 0.00% 0.01% 0.00% 0.06% 0.00% 0.07% 0.03% 0.01% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.01% 0.00% 0.06% 0.00% 0.07% 0.03% 0.01% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 247.60% 0.00% 0.00% 0.00%
Common Equity to Total Capital
100.00% 100.00% 100.00% 99.99% 100.00% 99.94% 100.00% -147.67% 99.97% 99.99% 100.00%
Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA
0.00 0.00 0.00 2.46 0.00 6.12 0.00 1.54 3.76 3.75 2.60
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT
0.00 0.00 0.00 3.37 0.00 8.15 0.00 2.07 5.07 5.40 3.72
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 8.66 9.30
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 101.19% 85.85% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
15.61 10.87 9.93 16.68 30.28 24.66 16.67 12.74 8.72 20.84 16.56
Quick Ratio
15.54 10.83 9.87 16.63 30.17 24.41 16.50 12.33 8.58 20.61 16.39
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-15 -22 -35 -28 -53 -24 -44 -56 -11 -67 -70
Operating Cash Flow to CapEx
-77,953.85% -4,239.27% -9,052.23% 0.00% -1,751.31% -1,107.48% -1,457.49% -2,368.79% -16,019.31% -8,738.00% -6,523.50%
Free Cash Flow to Firm to Interest Expense
0.00 -22,430.50 -8,756.58 -6,946.20 0.00 0.00 0.00 -27,918.45 -930.68 -5,573.96 -14,042.52
Operating Cash Flow to Interest Expense
0.00 -30,226.00 -11,179.50 -7,894.25 0.00 0.00 0.00 -26,412.00 -4,285.17 -5,883.58 -15,434.60
Operating Cash Flow Less CapEx to Interest Expense
0.00 -30,939.00 -11,303.00 -7,882.00 0.00 0.00 0.00 -27,527.00 -4,311.92 -5,950.92 -15,671.20
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.00 0.00 0.00 0.27 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
0.00 0.00 0.00 38.31 0.00 0.00 0.00 0.00 0.00 0.06 0.00
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
-4.52 -8.44 -9.20 -4.25 -1.41 -1.23 0.40 17 -11 -2.00 -4.12
Invested Capital Turnover
0.00 0.00 0.00 -3.72 0.00 0.00 0.00 0.00 0.00 -0.14 0.00
Increase / (Decrease) in Invested Capital
0.43 -3.92 -0.76 4.95 2.84 0.17 1.63 16 -28 9.06 -2.12
Enterprise Value (EV)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 89 170
Market Capitalization
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 402 439
Book Value per Share
$6.30 $6.18 $4.21 $3.09 $3.70 $4.56 $3.37 ($3.42) $19.79 $20.89 $17.10
Tangible Book Value per Share
$6.30 $6.18 $4.21 $3.09 $3.68 $4.56 $3.36 ($3.42) $19.79 $20.89 $17.10
Total Capital
108 145 99 73 142 191 143 99 186 310 265
Total Debt
0.00 0.00 0.00 0.01 0.00 0.11 0.00 0.07 0.07 0.03 0.01
Total Long-Term Debt
0.00 0.00 0.00 0.01 0.00 0.11 0.00 0.07 0.07 0.03 0.01
Net Debt
-113 -153 -108 -77 -143 -192 -142 -82 -197 -312 -269
Capital Expenditures (CapEx)
0.03 0.71 0.49 -0.05 0.88 2.22 3.26 2.23 0.32 0.81 1.18
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-4.48 -9.09 -10 -4.39 -4.24 -5.92 -7.11 -3.95 -20 -12 -14
Debt-free Net Working Capital (DFNWC)
70 94 98 73 139 187 135 78 177 301 255
Net Working Capital (NWC)
70 94 98 73 139 187 135 78 177 301 255
Net Nonoperating Expense (NNE)
6.92 11 14 8.75 20 9.67 18 16 -2.59 17 18
Net Nonoperating Obligations (NNO)
-113 -153 -108 -77 -143 -192 -142 -82 -197 -312 -269
Total Depreciation and Amortization (D&A)
0.00 0.00 0.36 0.29 0.53 1.82 2.28 3.20 3.19 0.83 -1.44
Debt-free, Cash-free Net Working Capital to Revenue
0.00% 0.00% 0.00% -17.56% 0.00% 0.00% 0.00% 0.00% 0.00% -1,258.27% 0.00%
Debt-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 290.15% 0.00% 0.00% 0.00% 0.00% 0.00% 32,515.24% 0.00%
Net Working Capital to Revenue
0.00% 0.00% 0.00% 290.15% 0.00% 0.00% 0.00% 0.00% 0.00% 32,515.24% 0.00%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($1.73) ($1.96) ($2.14) ($1.34) ($2.57) ($0.64) ($1.10) ($1.04) $0.00 ($4.28) ($4.24)
Adjusted Weighted Average Basic Shares Outstanding
17.21M 23.42M 23.49M 23.54M 38.37M 42.33M 55.04M 55.22M 0.00 17.57M 21.33M
Adjusted Diluted Earnings per Share
($1.73) ($1.96) ($2.14) ($1.34) ($2.57) ($0.64) ($1.10) ($1.04) $0.00 ($4.28) ($4.24)
Adjusted Weighted Average Diluted Shares Outstanding
17.21M 23.42M 23.49M 23.54M 38.37M 42.33M 55.04M 55.22M 0.00 17.57M 21.33M
Adjusted Basic & Diluted Earnings per Share
($1.73) ($1.96) ($2.14) ($1.34) ($2.57) ($0.64) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
12.64M 18.89M 23.45M 23.52M 27.03M 51.83M 42.49M 42.82M 12.85M 14.93M 15.57M
Normalized Net Operating Profit after Tax (NOPAT)
-15 -26 -36 -23 -50 -29 -42 -40 -39 -58 -72
Normalized NOPAT Margin
0.00% 0.00% 0.00% -91.35% 0.00% 0.00% 0.00% 0.00% 0.00% -6,251.19% 0.00%
Pre Tax Income Margin
0.00% 0.00% 0.00% -126.34% 0.00% 0.00% 0.00% 0.00% 0.00% -8,185.73% 0.00%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.00 -37,001.00 -12,544.75 -7,895.25 0.00 0.00 0.00 -28,262.00 -4,634.25 -7,014.42 -20,378.60
NOPAT to Interest Expense
0.00 -26,351.50 -8,945.83 -5,709.20 0.00 0.00 0.00 -19,780.95 -3,242.34 -4,818.63 -14,465.92
EBIT Less CapEx to Interest Expense
0.00 -37,714.00 -12,668.25 -7,883.00 0.00 0.00 0.00 -29,377.00 -4,661.00 -7,081.75 -20,615.20
NOPAT Less CapEx to Interest Expense
0.00 -27,064.50 -9,069.33 -5,696.95 0.00 0.00 0.00 -20,895.95 -3,269.09 -4,885.96 -14,702.52
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -3.80% 0.00%
Augmented Payout Ratio
-28.41% -12.68% 0.00% 0.00% -0.51% -1.07% 0.00% 0.00% 0.00% -3.80% -0.27%

Quarterly Metrics And Ratios for Neoleukin Therapeutics

This table displays calculated financial ratios and metrics derived from Neoleukin Therapeutics' official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding
12,852,985.00 12,980,289.00 12,993,613.00 - 14,929,566.00 14,262,066.00 14,271,916.00 15,489,800.00 15,574,293.00 15,801,901.00 20,011,382.00
DEI Adjusted Shares Outstanding
12,852,985.00 12,980,289.00 12,993,613.00 - 14,929,566.00 14,262,066.00 14,271,916.00 15,489,800.00 15,574,293.00 15,801,901.00 20,011,382.00
DEI Earnings Per Adjusted Shares Outstanding
-1.32 -1.42 -1.56 - -1.52 -1.54 -1.47 -1.60 -1.99 -2.18 -1.45
Growth Metrics
- - - - - - - - - - -
Revenue Growth
0.00% 0.00% 0.00% 0.00% 0.00% -100.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth
-55.50% -56.69% -42.05% -57.46% -41.23% -33.13% -8.15% -19.05% -21.91% -34.77% -41.42%
EBIT Growth
-48.65% -64.02% -45.83% -48.65% -33.38% -26.55% -7.39% -21.30% -28.41% -40.23% -35.93%
NOPAT Growth
-44.07% -59.84% -45.74% -46.01% -38.02% -29.54% -7.29% -27.98% -28.67% -40.60% -36.05%
Net Income Growth
-37.98% -55.92% -38.69% -918.88% -33.84% -19.06% -3.64% -26.76% -36.59% -56.65% -38.51%
EPS Growth
96.46% 95.91% 96.36% -101.14% -8.00% 3.67% 16.81% -12.00% -28.70% -45.71% -6.06%
Operating Cash Flow Growth
-59.72% -70.40% -34.54% -3.09% 4.05% -22.46% -25.34% 0.38% -25.73% -22.09% -49.40%
Free Cash Flow Firm Growth
-233.13% -191.89% -100.42% -238.42% 2.18% 10.69% -6.27% 28.89% -16.33% -17.86% 3.99%
Invested Capital Growth
159.84% 146.85% 52.86% 81.89% -163.50% -208.00% 108.90% -105.64% -582.91% -557.85% -3,692.70%
Revenue Q/Q Growth
0.00% 0.00% -100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth
-35.47% -6.18% -9.44% 0.50% -24.74% 0.46% 11.10% -7.25% -27.73% -10.66% 6.71%
EBIT Q/Q Growth
-31.40% -6.64% -7.41% 1.23% -21.07% -0.60% 8.85% -8.64% -28.17% -10.49% 11.65%
NOPAT Q/Q Growth
-27.46% -7.22% -10.16% 3.01% -20.49% -0.63% 8.75% -15.68% -21.14% -9.96% 11.71%
Net Income Q/Q Growth
-810.07% -9.28% -9.33% 3.48% -16.06% 2.79% 4.83% -18.05% -25.06% -11.49% 15.85%
EPS Q/Q Growth
-101.14% -9.00% -9.17% 15.97% -8.00% 2.78% 5.71% -13.13% -24.11% -10.07% 31.37%
Operating Cash Flow Q/Q Growth
-27.56% 26.59% 2.07% -12.41% -18.74% 6.32% -0.24% 10.66% -49.86% 9.03% -22.66%
Free Cash Flow Firm Q/Q Growth
-194.50% -7.70% 2.72% -39.82% 33.22% 1.67% -15.76% 6.44% -9.24% 0.38% 5.70%
Invested Capital Q/Q Growth
111.24% -6.59% -232.53% -30.13% 60.58% -58.86% 110.92% -3,108.03% -30.91% -53.03% 40.38%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
0.00% 100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin
0.00% -2,181.19% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin
0.00% -2,176.65% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin
0.00% -2,234.27% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin
0.00% -1,999.14% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent
99.16% 99.23% 99.30% 99.27% 100.00% 94.78% 99.29% 106.50% 100.00% 99.59% 99.51%
Interest Burden Percent
88.05% 90.17% 91.72% 89.66% 87.61% 88.81% 88.52% 89.68% 93.19% 94.42% 90.01%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
-32.50% -40.59% -50.08% -30.28% 0.00% -39.41% -42.25% -31.41% -37.25% -45.32% -38.42%
Cash Return on Invested Capital (CROIC)
-3,718.00% -4,461.92% 0.00% 0.00% 0.00% 0.00% -50,944.53% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
0.00% -15.09% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)
0.00% -13.51% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)
-32.50% -40.59% -50.08% -30.28% 0.00% -39.41% -42.25% -31.41% -37.25% -45.32% -38.42%
Return on Equity Simple (ROE_SIMPLE)
-23.99% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-13 -14 -16 -15 -18 -18 -17 -19 -23 -26 -23
NOPAT Margin
0.00% -1,523.65% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)
-2.99% -3.73% -4.31% -1.75% -1.95% -1.76% -2.12% -1.88% -2.83% -3.53% -2.03%
Return On Investment Capital (ROIC_SIMPLE)
-7.70% -9.09% -11.30% -4.85% -6.22% -6.68% -6.27% -7.28% -9.82% -11.82% -6.39%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
0.00% 574.59% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue
0.00% 1,702.05% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
0.00% 2,276.65% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)
-19 -21 -22 -22 -26 -26 -24 -26 -33 -37 -32
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-19 -20 -22 -22 -27 -27 -24 -26 -33 -36 -34
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
5.04 3.98 5.18 1.29 0.84 1.15 1.38 1.66 1.89 3.27 2.17
Price to Tangible Book Value (P/TBV)
5.04 3.98 5.18 1.29 0.84 1.15 1.38 1.66 1.89 3.27 2.17
Price to Revenue (P/Rev)
0.00 666.49 769.04 434.14 265.80 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
555.36 398.15 0.00 0.00 0.00 0.00 740.48 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
0.00 500.16 618.82 96.44 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage
-1.00 -1.01 -1.02 -1.03 -1.00 -1.00 -1.00 -1.01 -1.01 -1.02 -1.01
Leverage Ratio
1.17 1.17 1.19 1.12 1.10 1.11 1.12 1.09 1.09 1.10 1.07
Compound Leverage Factor
1.03 1.05 1.09 1.01 0.97 0.99 0.99 0.97 1.02 1.04 0.97
Debt to Total Capital
0.00% 0.03% 0.03% 0.01% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.03% 0.03% 0.01% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
100.00% 99.97% 99.97% 99.99% 99.99% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA
0.00 2.28 1.85 3.75 3.23 2.80 2.66 2.60 2.23 1.90 2.80
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT
0.00 3.19 2.62 5.40 4.66 4.10 3.90 3.72 3.14 2.65 3.96
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
20.22 13.78 14.41 9.27 5.82 7.18 9.07 10.17 9.22 13.76 19.16
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
14.74 12.17 9.09 20.84 21.03 18.07 18.39 16.56 13.08 10.64 19.97
Quick Ratio
14.35 11.77 8.80 20.61 20.76 17.78 18.04 16.39 12.89 10.48 19.81
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-16 -18 -17 -24 -16 -16 -18 -17 -19 -19 -18
Operating Cash Flow to CapEx
-33,307.69% -3,455.00% -9,319.76% -15,082.76% -2,663.33% -13,150.00% -15,360.63% -13,616.41% -9,295.02% -6,712.15% -9,252.38%
Free Cash Flow to Firm to Interest Expense
-5,489.43 -4,433.95 -5,751.00 -12,061.20 -8,054.65 -15,839.70 -18,335.60 -17,154.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
-7,216.67 -3,973.25 -5,188.00 -8,748.00 -10,387.00 -19,462.00 -19,508.00 -17,429.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
-7,238.33 -4,088.25 -5,243.67 -8,806.00 -10,777.00 -19,610.00 -19,635.00 -17,557.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.00 0.01 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
0.00 0.11 0.11 0.06 0.06 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
1.24 1.16 -1.54 -2.00 -0.79 -1.26 0.14 -4.12 -5.40 -8.26 -4.92
Invested Capital Turnover
0.00 -1.40 -0.38 -0.14 4.07 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital
3.32 3.64 1.73 9.06 -2.03 -2.42 1.68 -2.12 -4.61 -7.00 -5.06
Enterprise Value (EV)
691 463 572 89 -47 40 101 170 207 484 411
Market Capitalization
860 617 711 402 246 315 367 439 450 709 770
Book Value per Share
$13.29 $11.94 $10.58 $20.89 $19.54 $19.16 $18.61 $17.10 $15.27 $13.74 $17.73
Tangible Book Value per Share
$13.29 $11.94 $10.58 $20.89 $19.54 $19.16 $18.61 $17.10 $15.27 $13.74 $17.73
Total Capital
171 155 137 310 292 273 266 265 238 217 355
Total Debt
0.00 0.05 0.04 0.03 0.02 0.01 0.01 0.01 0.00 0.00 0.00
Total Long-Term Debt
0.00 0.05 0.04 0.03 0.02 0.01 0.01 0.01 0.00 0.00 0.00
Net Debt
-170 -154 -139 -312 -293 -275 -265 -269 -243 -225 -360
Capital Expenditures (CapEx)
0.07 0.46 0.17 0.12 0.78 0.15 0.13 0.13 0.28 0.35 0.32
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-7.21 -7.83 -11 -12 -10 -11 -9.60 -14 -15 -18 -15
Debt-free Net Working Capital (DFNWC)
162 146 128 301 282 264 256 255 228 207 345
Net Working Capital (NWC)
162 146 128 301 282 264 256 255 228 207 345
Net Nonoperating Expense (NNE)
3.78 4.40 4.69 4.46 4.50 3.76 4.29 5.46 7.59 8.82 6.36
Net Nonoperating Obligations (NNO)
-170 -154 -139 -312 -293 -275 -265 -269 -243 -225 -360
Total Depreciation and Amortization (D&A)
0.38 0.49 0.12 -0.16 -0.99 -0.71 -0.04 0.29 0.48 0.48 -1.37
Debt-free, Cash-free Net Working Capital to Revenue
0.00% -846.38% -1,204.97% -1,258.27% -1,113.30% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue
0.00% 15,792.00% 13,821.30% 32,515.24% 30,519.35% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue
0.00% 15,792.00% 13,821.30% 32,515.24% 30,519.35% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($1.00) ($1.09) ($1.19) ($1.00) ($1.08) ($1.05) ($0.99) ($1.12) ($1.39) ($1.53) ($1.05)
Adjusted Weighted Average Basic Shares Outstanding
16.90M 16.94M 16.95M 17.57M 21.00M 21.06M 21.17M 21.33M 22.31M 22.55M 27.70M
Adjusted Diluted Earnings per Share
($1.00) ($1.09) ($1.19) ($1.00) ($1.08) ($1.05) ($0.99) ($1.12) ($1.39) ($1.53) ($1.05)
Adjusted Weighted Average Diluted Shares Outstanding
16.90M 16.94M 16.95M 17.57M 21.00M 21.06M 21.17M 21.33M 22.31M 22.55M 27.70M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
12.98M 12.99M 14.85M 14.93M 14.26M 14.27M 15.49M 15.57M 15.80M 20.01M 20.70M
Normalized Net Operating Profit after Tax (NOPAT)
-13 -14 -16 -15 -18 -18 -17 -19 -23 -26 -23
Normalized NOPAT Margin
0.00% -1,523.65% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin
0.00% -2,014.70% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
-6,460.33 -5,166.75 -7,399.67 -10,963.00 -12,925.50 -26,155.00 -23,840.00 -25,899.00 0.00 0.00 0.00
NOPAT to Interest Expense
-4,381.77 -3,523.45 -5,175.33 -7,529.20 -9,071.65 -18,256.70 -16,658.60 -19,271.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
-6,482.00 -5,281.75 -7,455.33 -11,021.00 -13,315.50 -26,303.00 -23,967.00 -26,027.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
-4,403.43 -3,638.45 -5,231.00 -7,587.20 -9,461.65 -18,404.70 -16,785.60 -19,399.00 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
-6.97% -6.00% -5.36% -3.80% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
-6.97% -6.00% -5.36% -3.80% 0.00% 0.00% 0.00% -0.27% 0.00% -0.23% -0.06%

Financials Breakdown Chart

Key Financial Trends

Neurogene’s Q2 2026 statements show a well-capitalized but still pre-revenue biotechnology company. Revenue remained at $0, while the company reported a $34.5 million net loss and $23.8 million of cash used in operating activities. Losses and operating expenses have generally widened over the past several quarters as Neurogene increases investment in research and development.

The balance sheet remains a relative strength. As of June 30, 2026, Neurogene held $112.5 million in cash and $112.9 million in short-term investments, or approximately $225.4 million of highly liquid assets. Total liabilities were only $27.2 million compared with $217.1 million of equity, and the current ratio was approximately 10.6. However, liquid assets declined from $243.2 million in Q1 2026 and $273.5 million in Q2 2025, reflecting continued cash consumption.

  • Strong liquidity: Cash and short-term investments totaled approximately $225.4 million at the end of Q2 2026, providing a substantial funding base for clinical development.
  • Low leverage: Total liabilities were $27.2 million, with only about $3,000 in capital lease obligations and no meaningful interest expense. This limits near-term debt-related financial pressure.
  • Investment income provides some support: Interest and investment income was $2.0 million in Q2 2026, partially offsetting operating losses. Neurogene has generated between roughly $1.8 million and $3.2 million of quarterly investment income in the periods provided.
  • Research spending is being prioritized: Research and development expense rose to $25.5 million in Q2 2026 from $19.4 million in Q2 2025, suggesting increased investment in the company’s development programs.
  • Investment portfolio activity is substantial but not operational cash generation: Neurogene purchased $112.7 million of investments and received $119.1 million from investment sales or maturities in Q2 2026. The resulting $6.1 million of investing cash flow was largely portfolio management rather than business-generated cash.
  • Cash runway appears meaningful but is difficult to estimate precisely: The $225.4 million of liquid assets equates to approximately nine quarters of Q2 operating cash usage before considering changes in spending, financing, investment income, or clinical-program costs. This is not a formal runway forecast.
  • No commercial revenue has developed: Revenue was $0 in Q2 2026, consistent with most reported quarters in the supplied data. Neurogene therefore remains dependent on financing and its pipeline reaching commercial success.
  • Operating losses are worsening: The Q2 2026 net loss of $34.5 million exceeded the $30.9 million loss in Q1 2026 and the $22.0 million loss in Q2 2025. Operating expenses increased to $36.7 million from $26.1 million year over year.
  • Cash burn remains elevated: Operating cash outflow was $23.8 million in Q2 2026, following a $26.1 million outflow in Q1. The company’s net cash position declined by $11.7 million during the quarter despite positive investing and financing cash flows.
  • Shareholder dilution is a continuing risk: Weighted-average basic shares increased to 22.6 million in Q2 2026 from 21.1 million in Q2 2025. The increase raises the amount of future earnings and pipeline value that must be shared across a larger number of shares.
11/17/26 12:34 PM ETAI Generated. May Contain Errors.

Neoleukin Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Neoleukin Therapeutics' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Neoleukin Therapeutics' net income appears to be on a downward trend, with a most recent value of -$90.35 million in 2025, falling from -$21.86 million in 2015. The previous period was -$75.14 million in 2024.

Neoleukin Therapeutics' total operating income in 2025 was -$103.33 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $103.33 million

Over the last 10 years, Neoleukin Therapeutics' total revenue changed from $0.00 in 2015 to $0.00 in 2025, a change of 0.0%.

In the past 12 quarters, Neoleukin Therapeutics' cash and equivalents has ranged from $25.23 million in Q3 2023 to $150.14 million in Q1 2024, and is currently $78.94 million as of their latest financial filing in Q3 2026.

Neoleukin Therapeutics had total debt of $5 thousand at the end of 2025, a 80.8% decrease from 2024, and none in 2015.

Over the last 10 years, Neoleukin Therapeutics' book value per share changed from 6.30 in 2015 to 17.10 in 2025, a change of 171.5%.



Financial statements for NASDAQ:NLTX last updated on 11/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners